Global Drugs for Herpes Labialis Market Overview :
“The global Drugs for Herpes Labialis market size is expected to be worth around US$ 234.5 million by 2021 from US$ 141.2 million in 2031, growing at a CAGR of 5.19% during the forecast period 2021 to 2031.”
Herpes labialis is a viral infection caused by the herpes simplex virus 1 (HSV-1) this is commonly related to wounds due to cold or herpes simplex virus 2 (HSV-2). Herpes labialis usually occurs due to swellings of lips and around the facial area near the mouth.
Mostly the infection of herpes labialis occurs in childhood and to a certain extent is inactive in the nervous system. However, serious health consequences are seen between new-born babies or people who are immunosuppressed are affected
Global Drugs for Herpes Labialis Market: Dynamics
The major factor that is anticipated to drive growth of the global drugs for herpes labialis market is increasing prevalence’s of Herpes Labialis among children and adults across the globe. According to the World Health Organization, in 2012, an estimated 3.7 billion people under the age of 50, or 67% of the population, had HSV-1 infection. The estimated prevalence of the infection was highest in Africa (87%) and lowest in the Americas (40-50%).
In addition, increasing government expenditure on the healthcare sector, and innovative product offerings such as antiviral creams or ointments are some other factors expected to further support growth of the global market.
However, high cost of treatment and stringent government regulations related to drug approval are major factors expected to hamper growth of the global drugs for herpes labialis market. According to the National Center for Biotechnology Information, emergency department spending for herpes simplex viruses from 2006 to 2013 was US$ 45.0 Mn to US$ 90.7 Mn.
Rising government expenditure on the pharmaceutical sector, increasing investment by major players for R&D activities, and availability of cost-effective treatment are factors expected to create new opportunities in terms of revenue for players operating in the target market over the forecast period. In addition, increasing public-private partnerships for R&D activities are expected to further support growth of the global market to a certain extent.
Global Drugs for Herpes Labialis Market: Segment
Among the product segments, valacyclovir segment is expected to dominate in the target market over the forecast period.
Among the application segments, external use segment is expected to dominate in the target market over the forecast period.
Global Drugs for Herpes Labialis Market: Region
The market in North America is expected to dominate in the global drugs for herpes labialis market and is expected to continue its dominance over the forecast period. This can be attributed to well-developed pharmaceutical infrastructure for R&D activities and the presence of major players operating in the countries in this region. In addition, growing merger and acquisition activities between regional and international players are some other factors expected to further support growth of the target market in this region.
The market in Asia Pacific is expected to witness faster growth, owing to increasing government spending on the pharmaceutical sector and developing FDI policies is expected to create new opportunities for players in emerging economies in this region.
Global Drugs for Herpes Labialis Market Segmentation
Segmentation by product:
Segmentation by application:
- External Use
Segmentation by region:
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Attribute Report Details Market Size Ask For Market Size Growth Rate Ask For Growth Rate Key Companies Ask For Companies Report Coverage Revenue analysis, Competitive landscape, Key company analysis, Market Trends, Key segments, Distribution Channel, Market Dynamics, COVID-19 Impact Analysis and more… Historical Data Period 2015-2020 Base Year 2022 Forecast Period 2022-2031 Region Scope North America, Europe, Asia-Pacific, South America, Middle East & Africa Country Scope United States, Canada and Mexico, Germany, France, UK, Russia and Italy, China, Japan, Korea, India and Southeast Asia, Brazil, Argentina, Colombia etc.Saudi Arabia, UAE, Egypt, Nigeria and South Africa Revenue in US$ Mn
- GlaxoSmithKline plc
- Novartis AG
- Teva Pharmaceutical Industries Limited
- Mylan, Inc.
- Cadila Healthcare Limited
- Apotex Inc.
- Daewoong Pharmaceutical Co., Ltd.
- Livzon Pharmaceutical Group Inc.
- Shandong Luoxin Pharmaceutical Group Stock Company Limited
- Sichuan Med-shine Pharmaceutical Co Ltd.
- Bayer AG
Request for TOC
Why Choose Us
- 360 Degree Approach
- Growth Consulting
- 24/7 Research Support
- Comprehensive-Level of Customization
- Comprehensive-Level of Customization
- Competitive Intelligence
- Single-Country/ Region Intelligence
- Post-Sale Service Assistance
- Access to Lead Analysts
- Available in PDF, Excel, Word/ PPT
Request for Customization
Don't just take our word. We are trusted by these great companies!